Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8225375 | International Journal of Radiation Oncology*Biology*Physics | 2012 | 7 Pages |
Abstract
These findings demonstrate for the first time that amifostine is a normal liver radioprotector. They further suggest that it may be useful to combine amifostine with fractionated or stereotactic body radiation therapy for patients with focal intrahepatic cancer.
Keywords
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Mary M.D., David E. Ph.D., Daniel P. Ph.D., James A. M.D., Charlie C. M.D., Edgar M.D., Zheng Ph.D., Meihua R. Ph.D., Jun Ph.D., William M.D., Theodore S. Ph.D., M.D.,